



Press Release

Capsulation and Schering extend cooperation in research and development

Berlin based companies sign agreement to develop new contrast agents and imaging methods in the field of magnetic resonance technology.

Berlin, June 08th 2006 - Capsulation NanoScience AG, the Berlin based nanotechnology company that is specialised in the development of innovative packaging systems for active substances, has signed a development contract with the Schering AG, Berlin (FSE: SCH; NYSE: SHR). Goal of the cooperation is to develop new contrast agents resp. imaging methods in the field of magnetic resonance technology. The projects focuses on the early diagnosis and treatment of the two most relevant cancer types, the breast and prostate tumors.

Substantial advances in sensitive imaging methods and special directed contrast agents are indispensable for an early diagnosis and individual therapy of these types of cancer. Capsulations specially tuned nanocapsules can be a great help in this field. Dr. Andreas Voigt, CSO of Capsulation mentioned: "The effects of cancer disease can be reduced, if the personal risk of developing cancer can be determined at an early state via our LBL-Technologie®." In addition to radio pharmaceuticals, it is possible to use special nanotechnology concepts based on the colloid and interface research; for example magnetized nanocapsules which are linked to targeted ligands.

The project called "Eisenherz" is supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the leading innovation program "Nano-for-Life". Other partners, like Philips Medizin Systeme GmbH, Siemens AG, Max-Planck Institute (MPI) of Colloids and Interfaces or the German Cancer Research Center are also involved in the project.

Contact person

Schering AG
Dr. Andreas Briel

Email: andreas.briel@schering.de

Capsulation Nanoscience AG
Herr Dipl.-Kfm. Alexander Herrmann

Telefon: +49 (0)30-63 92 36 00
Fax: +49 (0)30-63 92 36 01
alexander.herrmann@capsulation.com



About Capsulation NanoScience AG

Capsulation NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. In order to meet customers needs for complete product solutions Capsulation has recently designated a Japanese licensee as the preferred developer, manufacturer and distributor for automated LBL-units. Only six month after the signing of the licence agreement, EBARA has started operation of the first prototype plant (LBL-Unit®) for the manufacture of Capsulation's LBL capsules. In 2005, renowned growth consultants Frost & Sullivan have awarded the year's "Product Differentiation Innovation Award" in the global nanobiotechnology market to Capsulation NanoScience AG, Berlin. The company has received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Press Release and Press Box online:

<http://www.pressebox.de/pressefach/capsulation-nanoscience-ag>